AMICUS THERAPEUTICS, INC. — Director's Dealing 2022

Jan 19, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2022-01-14

Reporting Person: Crowley John F (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-14	Common Stock	A	239099	—	Acquired	894230	Direct
2022-01-14	Common Stock	A	149660	—	Acquired	1043890	Direct
2022-01-14	Common Stock	F	58891	$10.53	Disposed	984999	Direct
2022-01-18	Common Stock	S	8564	$10.23	Disposed	976435	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-14	Stock Options (right to buy)	$12.11	A	438222	Acquired	2032-01-14	Common Stock (438222)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	64895	Indirect

Footnotes

F1: Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock.

F2: The Restricted Stock Units will vest in four equal annual installments beginning on January 3, 2023.

F3: Granted for the achievement of the 2019 PRSU TSR goal as determined by the Board of Directors.

F4: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5: These options vest and become exercisable in a series of installments over a four year period, with 25% vesting on January 3, 2023 and the remaining 75% vesting ratably each month thereafter.